Luminex Corporation Hosts Eighth Annual Planet xMAP Europe in Vienna

Two-Day Multiplexing Symposium Brings Together Leading Scientists to Discuss New Developments in Clinical Diagnostics and Life Science Research

OOSTERHOUT, Netherlands, October 13, 2010 - Luminex Corporation (Nasdaq: LMNX), today announced that it will host
Planet xMAP Europe 2010, its annual European multiplexing technology
symposium, October 20-21, 2010, at The Hofburg in Vienna, Austria. The event
will feature scientific sessions, workshops, discussion groups, exhibitions
and networking events with scientists and researchers from around the world
who are performing groundbreaking work in clinical diagnostics and life
science research using Luminex's xMAP(R) multiplexing technology platform.

    (Logo: photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
    (Logo: www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

"Planet xMAP Europe is an excellent opportunity for scientists to gather
and exchange ideas on how xMAP multiplexing technology is revolutionizing
their laboratories and research," said Paul C. Ladestein, General Manager
European Operations for Luminex. "We look forward to welcoming these leading
scientists to our exciting new venue at The Hofburg in Vienna."

Planet xMAP Europe 2010 will feature two days of presentations with six
focused session options.

Day One of Planet xMAP Europe 2010, Wednesday, 20 October, will focus on
Pathogen Detection, Immunology-Monitoring and HLA-Human Genetics.

The morning session will include the following presentations:

- Professor Sabine Bahn, MD, PhD, MRCPsych, of the Cambridge Centre for
Neuropsychiatric Research Institute of Biotechnology, University of
Cambridge, UK, "Disease Biomarkers in First-onset Schizophrenia"

- Professor Jean Louis Merlin, PharmD, PhD, of Tumor Biology Unit, Nancy
University Centre Alexis Vautrin, Vandoeuvre-les-Nancy, France,
"Phosphoprotein array for characterization of Human Tyrosine kinase receptors
downstream signaling functionality as response predictive marker to targeted
therapy in translational oncology research programs"

- Professor Alex van Belkum, Department of Medical Microbiology and
Infectious Diseases Erasmus MC, Rotterdam, The Netherlands, "Multi-parameter
assessment of the humoral response to colonisation and infection with
opportunistic microbial pathogens from the human Nasopharyngeal cavity"

- Professor Jonas Blomberg, Section of Virology, Department of Medical
Sciences, Uppsala University, Sweden, "More for less; multiplex broadly
targeted nucleic acid and serology analyses from the same clinical sample"

- Tim Dehne, Vice President of Systems Research and Development, Luminex
Corporation, "MAGPIX: The Next Dimension in Multiplexing"

The afternoon session will feature three separate tracks focused on
Pathogen Detection, Immunology-Monitoring, and Human Genetics.

Day Two of Planet xMAP Europe 2010, Thursday, 21 October, will focus on
Protein and Genomic Research, and xTAG RVP Fast.

The morning session will include the following presentations:

- Carlo M. Croce, MD, Department of Molecular Virology, Immunology and
Medical Genetics The Ohio State University Medical Center, Columbus, Ohio,
USA, "Causes and consequences of microRNA Dysregulation in cancer"

- Nicholas Haining, Assistant Professor of Pediatrics, Department of
Pediatric Oncology Dana-Farber Cancer Institute, Harvard Medical School,
Boston, MA, USA, "Gene-expression based high-throughput screening"

- Anna E. Lokshin, PhD, Hillman Cancer Institute, Luminex Core Facility,
University of Pittsburgh, USA, "Urine as a source of cancer biomarkers"

The afternoon session will feature a special xTAG RVP Fast Workshop on
current and future trends in respiratory viral testing.

For detailed information regarding the Planet xMAP Europe 2010 symposium
and agenda, or to register online, please visit www.planetxmap.com.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the diagnostic
and life sciences industries. The Company's xMAP(R) multiplex solutions
include an open-architecture, multi-analyte technology platform that delivers
fast, accurate and cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical research,
including the genomics and proteomics markets. The Company's xMAP technology
is sold worldwide and is already in use in leading clinical laboratories as
well as major pharmaceutical, diagnostic and biotechnology companies. Further
information on Luminex Corporation or xMAP can be obtained at
www.luminexcorp.com.

    Luminex Corporate Contact:
    Harriss T. Currie
    Vice President, Finance and Chief Financial Officer
    +1-512-219-8020

    Matthew Scalo
    Sr. Director Investor Relations
    +1-512-219-8020
    mscalo@luminexcorp.com

    Luminex Media Contact:
    Aaron De Lucia
    +1-512-241-2249
    aaron.delucia@porternovelli.com

Corporate, Harriss T. Currie, Vice President, Finance and Chief Financial Officer, or Matthew Scalo, Sr. Director Investor Relations, mscalo at luminexcorp.com, both of Luminex Corp., +1-512-219-8020; or Media, Aaron De Lucia, +1-512-241-2249, aaron.delucia at porternovelli.com, for Luminex Corp.